Double blind randomized clinical trial controlled by placebo with a FOS enriched cookie on saciety and cardiovascular risk factors in obese patients

被引:11
|
作者
de Luis, D. A. [1 ,2 ]
de la Fuente, B. [1 ,2 ]
Izaola, O. [1 ,2 ]
Aller, R. [1 ,2 ]
Gutierrez, S. [3 ]
Morillo, Maria [4 ]
机构
[1] Univ Valladolid, Fac Med, Inst Endocrinol & Nutr, Simancas 47130, Valladolid, Spain
[2] Univ Valladolid, Hosp Rio Hortega, Unidad Apoyo Invest, Simancas 47130, Valladolid, Spain
[3] CARTIF, Div Invest Gullon SA, Valladolid, Spain
[4] CARTIF, Div Aliment, Valladolid, Spain
关键词
Cardiovascular risk factors; Cookies; FOS; Satiety; Obesity; OLIGOFRUCTOSE PROMOTES SATIETY; MEAL INTAKE; HIGH-FAT; APPETITE; ENERGY; FOOD; SNACK; DIET; AIR;
D O I
10.3305/nh.2013.28.1.6255
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Introduction: It is essential to determine which snack foods are most affective for appetite control. The objective of the current study was to assess the responses of two different cookies on satiety and cardiovascular risk factors. Material and Methods: 38 patients were randomized: group I (FOS enriched cookie, n=19) and group II (control cookie, n=19). Previous and after 1 month, the subjects rated their feelings of satiety/hunger with a test meal of 5 cookies. Results: After the test meal, the basal area under curve of the first hunger/satiety score was higher with satiety cookie than with control cookie, the data after 1 month of treatment was higher with satiety cookie than with control cookie, too. The score was higher than the fasting level for 20 minutes with satiety cookie and for 40 minutes with the same cookie, too. In satiety group, these scores (20 min and 40 min) were higher than control group before and after 1 month of treatment. The results were in the same way with the 100 mm 5-point visual satiety scale. Cardiovascular risk factors and dietary intake remained unchanged after dietary intervention. Conclusion: A FOS enriched cookie produced greater ratings of satiety than a control cookie, without effects on cardiovascular risk factors or dietary intakes. (Nutr Hosp. 2013;28:78-85) DOI:10.3305/nh.2013.28.1.6255
引用
收藏
页码:78 / 85
页数:8
相关论文
共 50 条
  • [31] The effects of nanocurcumin on immune-related factors in the ankylosing spondylitis patients: a double-blind, randomized, placebo‐controlled clinical trial
    Halmat M. Jaafar
    Dana Muhammad Hamad Ameen
    Talar Ahmad Merza Mohammad
    Aziz Muzafar Jafaar
    Molecular Biology Reports, 2025, 52 (1)
  • [32] A Double-Blind, Randomized, Placebo-Controlled Clinical Trial on Benfotiamine Treatment in Patients With Diabetic Nephropathy
    Alkhalaf, Alaa
    Klooster, Astrid
    van Oeveren, Willem
    Achenbach, Ulrike
    Kleefstra, Nanne
    Slingerland, Robbert J.
    Mijnhout, G. Sophie
    Bilo, Henk J. G.
    Gans, Reinold O. B.
    Navis, Gerjan J.
    Bakker, Stephan J. L.
    DIABETES CARE, 2010, 33 (07) : 1598 - 1601
  • [33] Efficacy and safety of Hemoheal cream in patients with hemorrhoids: a randomized double-blind placebo controlled clinical trial
    Zobeiri, Mehdi
    Parvizi, Fatemeh
    Rahimi, Roja
    Heydarpour, Fatemeh
    Sheikhan, Hamid Reza
    Navabi, Jafar
    Farzaei, Mohammad Hosein
    JOURNAL OF TRADITIONAL CHINESE MEDICINE, 2021, 41 (02) : 301 - 307
  • [34] Randomized, Placebo-Controlled, Double Blind, Crossover Clinical Trial With Zolpidem In Patients With Impaired Level Of Consciousness
    O'Valle Rodriguez, Myrtha
    Moliner Munoz, Belen
    Navarro Perez, Ma Dolores
    Balmaseda Serrano, Raquel
    Colomer Font, Carolina
    Ferri Campos, Joan
    Noe Sebastian, Enrique
    BRAIN INJURY, 2012, 26 (4-5) : 519 - 520
  • [35] Efficacy and safety of Hemoheal cream in patients with hemorrhoids: a randomized double-blind placebo controlled clinical trial
    Mehdi Zobeiri
    Fatemeh Parvizi
    Roja Rahimi
    Fatemeh Heydarpour
    Hamid Reza Sheikhan
    Jafar Navabi
    Mohammad Hosein Farzaei
    JournalofTraditionalChineseMedicine, 2021, 41 (02) : 301 - 307
  • [36] Treatment of patients with undifferentiated arthritis with methotrexate: A double-blind placebo-controlled randomized clinical trial
    van Dongen, H.
    van Aken, J.
    Lard, L. R.
    Ronday, H. K.
    Speyer, I.
    Westedt, M. L.
    Allaart, C. F.
    Breedveld, F. C.
    Huizinga, T. W. J.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2006, 35 : 16 - 16
  • [37] The Effect of Curcumin on some of Traditional and Non-traditional Cardiovascular Risk Factors: A Pilot Randomized, Double-blind, Placebo-controlled Trial
    Mirzabeigi, Parastoo
    Mohammadpour, Amir Hooshang
    Salarifar, Mojtaba
    Gholami, Kheirollah
    Mojtahedzadeh, Mojtaba
    Javadi, Mohammad Reza
    IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH, 2015, 14 (02): : 479 - 486
  • [38] A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL OF TOLVAPTAN IN HYPONATREMIC PATIENTS WITH CANCER
    Ali, N.
    Palla, S.
    George, M.
    Salahudeen, A.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2013, 61 (02) : 501 - 501
  • [39] Effect of puerarin supplementation on cardiovascular disease risk factors: A randomized, double-blind, placebo-controlled, 2-way crossover trial
    Kwok, Man Ki
    Leung, Gabriel Matthew
    Xu, Lin
    Tse, Hung Fat
    Lam, Tai Hing
    Schooling, C. Mary
    BIOMEDICINE & PHARMACOTHERAPY, 2022, 153
  • [40] Randomized placebo controlled double blind pilot trial of Ramipril in McArdle disease patients
    Liava, A.
    Trevisi, E.
    Frare, M.
    Tonon, C.
    Malucelli, E.
    Manners, D.
    Kemp, G.
    Testa, C.
    Barbiroli, B.
    Lodi, R.
    Martinuzzi, A.
    NEUROMUSCULAR DISORDERS, 2007, 17 (9-10) : 860 - 861